Journal
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
Volume 4, Issue 1, Pages 213-225Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.0c00178
Keywords
immuno-oncology; computational biology; mathematical model; immunocompromised mice; patient-derived xenograft; PBMC humanized mice
Categories
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc.
- NIH [R01CA138264, U01CA212007]
Ask authors/readers for more resources
Immunotherapy has shown promising results in cancer treatment, but translational challenges remain in preclinical studies. The developed QSP model for humanized mice provides accurate data simulation and calibration, which can be an important tool for preclinical drug development.
Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-. were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available